Effect of a 36-month pharmaceutical care program on coronary heart disease risk in elderly diabetic and hypertensive patients

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 2, 2011, Pages 249-263

  Neto, Paulo Roque Obreli ^a   Marusic, Srecko ^b   de Lyra, Divaldo Pereira ^c   Pilger, Diogo ^d   Cruciol Souza Jr , Joice Mara ^e   Gaeti, Walderez Penteado ^a   Cuman, Roberto Kenji Nakamura ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b University of Zagreb School of Medicine   (Croatia)

^c FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^e STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

EID: 79961163634     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3259q     Document Type: Article

References (43)

1. WHO. Cardiovascular diseases (CVD). In: http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
2. Azambuja MIR, Foppa M, Maranhão MFC, Achutti AC. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arq Bras Cardiol, 2008; 91:163-171.
3. Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm, 1990; 47:543-553.
4. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother, 2007; 41:1770-1781.
5. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother, 2007; 41:1569-1582.
6. Machado M, Nassor N, Bajcar JM, et al. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42:1195-1207.
7. Christensen DB, Farris KB. Pharmaceutical care in community pharmacies: practice and research in the US. Ann Pharmacother. 2006; 40:1400-1406.
8. Noyce PR. Providing patient care through community pharmacies in the UK: policy, practice, and research. Ann Pharmacother. 2007; 41:861-868.
9. Benrimoj SI, Roberts AS. Providing patient care in community pharmacies in Australia. Ann Pharmacother. 2005; 39:1911-1917.
10. Sá-Borges AP, Guidoni CM, Ferreira LD, Freitas O, Pereira LRL. The pharmaceutical care of patients with type 2 diabetes. Pharm World Sci, 2010; 32:730-736.
11. Silva GEC, Bazotte RB. Development and evaluation of a pharmaceutical care program to reduce modifiable risk of chronic complications in Brazilian type 2 diabetes. Lat Am J Pharm, 2011; 30:154-160.
12. Lyra DP, Marcellini PS, Pelá IR. Effect of pharmaceutical care intervention on blood pressure of elderly outpatients with hypertension. Braz J Pharm Sci, 2008; 44:451-457.
13. Obreli-Neto PR, Cuman RKN. Pharmaceutical care program for the rational use of drugs in the elderly users of a Basic Health Unit in the Sao Paulo State, Brazil. Lat Am J Pharm, 2010; 29:333-339.
14. Correr CJ, Pontarolo R, Wiens A, Rossignoli P, Melchiors AC, Radominski R, Fernandez-Llimós F. Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies. Arq Bras Endocrinol Metab, 2009; 53:825-833.
15. Brasil. Lei N. 8080, 19 de setembro de 1990. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. Diário Oficial da União, Sept 20, 1990.
16. Brasil. Lei N. 8142, de 28 de dezembro de 1990. Dispõe sobre a participação da comunidade na gestão do Sistema Único de Saúde (SUS) e sobre as transferências intergovernamentais de recursos financeiros na área da saúde e dá outras providências. Diário Oficial da União, Dec 30, 1990.
17. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA, 2001; 285:2486-2497.
18. Academic Health Center Task Force on Interdisciplinary Health Team Development. Developing health care teams. St. Paul: The Supreme Court of Minnesota, 1996.
19. Brazilian Society of Cardiology, Brazilian Society of Hypertension, Brazilian Society of Nephrology. V Brazilian Guidelines on Hypertension. Arq Bras Cardiol, 2007;89:24-79.
20. Brazilian Society of Diabetes, Brazilian Society of Diabetes' Guidelines 2009. Diagraphic, Rio de Janeiro, RJ, Brazil, 2009.
21. Department of Atherosclerosis of Brazilian Society of Cardiology. IV Brazilian Guidelines on Dyslipidemia and Management of Atherosclerosis. Arq Bras Cariol, 2007; 88:1-19.
22. Larson LN, Rovers JP, MacKeigan LD. Patient satisfaction with pharmaceutical care: update of a validated instrument. J Am Pharm Assoc, 2002; 42:44-50.
23. Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des, 2004; 19:3987-4001.
24. Bloch KV, Melo AN, Nogueira AR. Prevalence of anti-hypertensive treatment adherence in patients with resistant hypertension and validation of three indirect methods for assessing treatment adherence. Cad Saude Publica, 2008; 24:2979-2984.
25. Krass I, Taylor SJ, Carlene S, Armour CL. Impact on medication use and adherence of Australian Pharmacist's Diabetes Care Services. J Am Pharm Assoc, 2005; 45:33-40.
26. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medication adherence. Med Care, 1986; 24:67-74.
27. Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, Cipolle RJ. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc, 2008;48:203-211.
28. Al-Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol, 2009; 67:547-557.
29. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care, 2005; 28:771-776.
30. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA, 2006; 296:2563-2571.
31. Castro MS, Fuchs FD, Santos MC, Maximiliano P, Gus M, Moreira LB, Ferreira MB. Pharmaceutical care program for patients with uncontrolled hypertension: report of a double-bind clinical trial with ambulatory blood pressure. Am J Hypertens, 2006; 19:528-533.
32. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm, 2005; 11:763-771.
33. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med, 2010; 363:2211:2219.
34. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet, 2009; 373:1083-1096.
35. Coutinho T, Goel K, Corrêa de Sá D, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, Torp-Pedersen C, Cottin Y, Lorgis L, Lee SH, Kim YJ, Thomas R, Roger VL, Somers VK, Lopez-Jimenez F. Central obesity and survival in subjects with coronary artery disease a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol, 2011; 57:1877-1886.
36. Ahrens RA, Hower M, Best AM. Effect of weight reduction interventions by community pharmacists. J Am Pharm Assoc, 2003; 43:583-590.
37. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of corona ry heart diseas e in type II dia b etes (UKPDS 56). Clin Sci, 2001; 101:671-679.
38. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 2002; 33:1776-1781.
39. Correr CJ, Melchiors AC, Fernandez-Llimos F, Pontarolo R. Effects of pharmacotherapy follow-up in community pharmacies on type 2 diabetes in Brazil. Int J Clin Pharm, 2011; 273-280.
40. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care, 2009; 32:S13-61.
41. Brouker ME, Gallagher K, Larrat EP, Dufresne RL. Patient compliance and blood pressure control on a nuclear-powered aircraft carrier: impact of a pharmacy officer. Mil Med, 2000; 165:106-110.
42. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care, 2007; 30:1292-1293.
43. Brawley LR, Culos-Reed SN. Studying adherence to therapeutics regimens: overview, theories, recommendations. Control Clin Trials, 2000; 21:156-163.